

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) IS NOW AVAILABLE THROUGH NEWFOUNDLAND AND LABRADOR PRESCRIPTION DRUG PROGRAM

TORONTO, March 10, 2021 - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed through the Newfoundland and Labrador Prescription Drug Program (NLPDP) under Special Authorization.

“The inclusion of RADICAVA on the Newfoundland and Labrador public formulary is a vital step in our long-term commitment to the ALS community,” said Atsushi Fujimoto, President, MTP-CA. “We thank the Government of Newfoundland and Labrador for its leadership in making this treatment available to patients who are eligible for coverage under the Newfoundland and Labrador Prescription Drug Program.”

In addition to the NLPDP, RADICAVA is also listed on provincial drug plans as follows:

- Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization)
- Ontario Drug Benefit Formulary (Exceptional Access Program)
- Alberta Drug Benefit List (special authorization)
- New Brunswick Drug Plan (NBDP) formulary (special authorization)
- Manitoba Drug Benefits and Interchangeability Formulary (special authorization)
- Saskatchewan Formulary (special authorization)
- Nova Scotia Drug Formulary (special authorization)
- British Columbia (BC) PharmaCare Formulary (special authorization)

In addition, RADICAVA is reimbursed by Veterans Affairs Canada (VAC) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB) Program.

MTP-CA continues to have discussions regarding the listing of RADICAVA under additional publicly funded drug programs.

About RADICAVA® (edaravone)

RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRSR).¹ Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.

About Mitsubishi Tanabe Pharma Canada, Inc.

Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit: <https://www.mt-pharma.ca.com/>.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned

subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.

Media inquiries:

Debbie Etchison

908-340-8578

media@mt-pharma-us.com

¹ RADICAVA® (edaravone) Canada Product Monograph. October 2019. <https://www.mt-pharma-ca.com/our-product/>